LY96

Across TCGA pan-cancer cohorts, LY96 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LY96 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher LY96 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LY96 expression acts as an unfavorable survival marker, although some lineages such as OV and SKCM show a favorable association.

COAD, CESC, and OV are the cancer types where LY96 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.362	0.877	<.001	48	view →
CESC	DFS	Median	All	0.126	0.826	<.001	36	view →
OV	DFS	Median	III,IV	1.000	0.149	.027	8	view →
SKCM	DFS	Median	II,III,IV	0.706	0.218	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LY96–COAD (OS)

Open the COAD breakdown →